Idiopathic Pulmonary Fibrosis (IPF) ― Common Practice in Poland Before the “Antifibrotic Drugs Era”

Advances in Respiratory Medicine - Poland
doi 10.5603/arm.2017.0023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

VM Media SP. zo.o VM Group SK

Related search

Prs27 - Economic Burden of Idiopathic Pulmonary Fibrosis (Ipf) in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

HDAC Inhibitors as Antifibrotic Drugs in Cardiac and Pulmonary Fibrosis

Therapeutic Advances in Chronic Disease
Medicine
2019English

Emerging Drugs for Idiopathic Pulmonary Fibrosis

Expert Opinion on Emerging Drugs
Pharmacology
2011English

FRI0461 Efficacy and Safety of Antifibrotic Agents in Idiopathic Pulmonary Fibrosis

2018English

Comparison of the Antifibrotic Effects of the Pan-Histone Deacetylase-Inhibitor Panobinostat Versus the IPF-drug Pirfenidone in Fibroblasts From Patients With Idiopathic Pulmonary Fibrosis

PLoS ONE
Multidisciplinary
2018English

Prs58 - Patients With Idiopathic Pulmonary Fibrosis (Ipf): What Happens Before the Diagnosis? A Real-World, Retrospective, Primary Care Database Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Idiopathic Pulmonary Fibrosis in Sweden: Report From the First Year of Activity of the Swedish IPF-Registry

European Clinical Respiratory Journal
2016English

Idiopathic Pulmonary Fibrosis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Diagnosis of Idiopathic Pulmonary Fibrosis “Pragmatic Challenges in Clinical Practice”

Frontiers in Medicine
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy